<DOC>
	<DOCNO>NCT02244762</DOCNO>
	<brief_summary>Determine influence renal impairment pharmacokinetics metabolism Hydrocodone Bitartrate Extended-Release ( HC-ER ) 20 mg capsule</brief_summary>
	<brief_title>Pharmacokinetics Metabolism Hydrocodone Bitartrate Extended-Release ( HC-ER ) Subjects With Renal Impairment</brief_title>
	<detailed_description>Pharmacokinetics relative bioavailability hydrocodone metabolite fast condition</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Hydrocodone</mesh_term>
	<criteria>All renalimpaired subject must meet follow inclusion criterion eligible enrol study . Subjects eligible study meet follow criterion : 1 . Male nonpregnant , nonlactating female . 2 . Subjects 1880 year old . 3 . Subjects must clinical diagnosis chronic renal impairment duration least 6 month classify mild , moderate severe per Cockcroft Gault criterion ( see Appendix A ) 4 . Renal insufficiency stable acute episode illness within previous 2 month due deterioration renal function due etiology . 5 . Female subject childbearing potential include tubal ligation surgery exclude experienced menstrual period minimum 2 year , must negative pregnancy test Screening Day 1 visit , must consent use medicallyacceptable method contraception throughout entire study period 1 week study complete . Medically acceptable method contraception include limited abstinence , birth control pills patch , vaginal ring , diaphragm vaginal spermicide , intrauterine device ( IUD ) , progestin implant injection ( use consistently 3 month prior study dose ) . 6 . Subjects must voluntarily provide write informed consent . 7 . Subjects , Investigator 's opinion , must able complete study procedure . All healthy control subject must meet renal subject inclusion criterion outline exception Inclusion Criteria 2 3 substitute follow enrol study : 2a . Must match age ( ± 10 year ) BMI ( ±10 % BMI ) consideration race gender subject renal impairment . 3b . Were medically healthy clinically significant abnormality laboratory profile deem investigator . Subjects eligible study meet follow criterion : 1 . Women pregnant breastfeeding . 2 . Any clinically significant condition would , opinion Investigator , preclude study participation . 3 . Uncontrolled blood pressure , i.e. , subject sit systolic blood pressure &gt; 180 mmHg &lt; 90 mmHg , and/or sit diastolic blood pressure &gt; 120 mmHg &lt; 50 mmHg screening . 4 . A Body mass Index ( BMI ) &gt; 40 kg/m2 . 5 . A known allergy hypersensitivity hydrocodone , opioids . 6 . Have take investigational drug within 30 day prior Day 1 visit currently enrol another investigational drug study . 7 . Have use monoamine oxidase inhibitor within 14 day prior Day 1 visit . 8 . Were take opioids 30 day prior Day 1 need take opioids study period . 9 . Positive HIV . Healthy control subject must Hepatitis C Virus ( HCV ) positive , renalimpaired subject HCV positive receiving treatment . 10 . A history illicit substance abuse past 2 year history opioids abuse . Subjects current abuser alcohol must negative serum alcohol Screening Day1 . 11 . Had positive quantitative urine drug screen illicit drug , nonprescribed controlled substance screen . 12 . Had make plasma donation within 7 day prior Day 1 . 13 . Had make significant donation loss blood within 56 day prior Day 1 . 14 . Had take CYP2D6 and/or 3A4 inhibitor within 7 day prior Day 1 and/or CYP2D6 and/or 3A4 inducer within 21 day prior Day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>